Literature DB >> 10368976

Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry.

M Jemal1, Z Ouyang, B C Chen, D Teitz.   

Abstract

A method for simultaneous quantitation of both the acid and lactone forms of atorvastatin, a new synthetic inhibitor of HMG-CoA reductase that is being marketed for the treatment of high serum cholesterol, and both the acid and lactone forms of its two biotransformation products, 2-hydroxyatorvastatin and 4-hydroxyatorvastatin, in human serum (a total of six analytes) by high-performance liquid chromatography with electrospray tandem mass spectrometry was developed and validated. A deuterium labeled analog was used as internal standard for each of the six analytes. Each point of the calibration standard curve, which ranged from 0.5 to 200 ng/mL, contained the six analytes at equal concentrations. Three groups of quality control (QC) samples were used. In the first group, combination QC samples contained all six analytes at equal concentrations. In the second group, acid-only QC samples contained only the acid forms (i.e. three analytes) at equal concentrations. In the third group, lactone-only QC samples contained only the lactone forms (i.e. three analytes) at equal concentrations. After adding the internal standard to 0.5 mL of each standard and the QC sample kept at 4 degrees C, the samples were acidified with sodium acetate buffer (pH 5.0) and then extracted with methyl tert-butyl ether. Detection was by positive ion electrospray tandem mass spectrometry using eight selected reaction monitoring channels. The acid compounds were stable in human serum at room temperature but the lactone compounds were unstable as they hydrolyzed rapidly to their respective acid forms. The conversion of the lactone compounds in both QC and post-dose human serum samples was nearly complete after 24 h at room temperature. The lactone compounds in serum could be stabilized by lowering the working temperature to 4 degrees C or lowering the serum pH to 6.0. The acid-only and the lactone-only QC samples showed that, under the sample processing conditions used, the degree of the hydrolysis of the lactone compounds or the lactonization of the acid compounds during the assay procedure was minimal (< 5%). The intra-day C.V., inter-day C.V. and the deviations from the nominal concentrations for all six analytes were within 15%, demonstrating good precision and accuracy. The required lower limit of quantitation (LLQ) of 0.5 ng/mL was achieved for each analyte.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368976     DOI: 10.1002/(SICI)1097-0231(19990615)13:11<1003::AID-RCM597>3.0.CO;2-L

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  14 in total

1.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

Review 2.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

3.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

5.  Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.

Authors:  Jiang Wang; Jasmine A Luzum; Mitch A Phelps; Joseph P Kitzmiller
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-01-13       Impact factor: 3.205

6.  A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.

Authors:  Peter S Kruger; Noelle M Freir; Bala Venkatesh; Thomas A Robertson; Michael S Roberts; Mark Jones
Journal:  Intensive Care Med       Date:  2008-11-26       Impact factor: 17.440

7.  Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats.

Authors:  Hazem F Elewa; Anna Kozak; Azza B El-Remessy; Reginald F Frye; Maribeth H Johnson; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

Review 8.  Clinical pharmacokinetics of atorvastatin.

Authors:  Hans Lennernäs
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting.

Authors:  O Moradi; I Karimzadeh; D Davani-Davari; M Shafiekhani; M M Sagheb; G A Raees-Jalali
Journal:  Int J Organ Transplant Med       Date:  2020

10.  Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products.

Authors:  Pallavi Vukkum; J Moses Babu; R Muralikrishna
Journal:  Sci Pharm       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.